Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV

Fixed-dose bictegravir-emtricitabine-tenofovir (Biktarvy) maintains virologic suppression in adults with HIV-1 who are switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens, according to results from two noninferiority trials.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: HIV/AIDS News Source Type: news